Medically reviewed by Sohaib Imtiaz, MD Key Takeaways Many factors affect the speed at which a person loses weight, including ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

Patients with overweight/obesity receiving branded semaglutide via a nationwide telehealth platform achieve weight-loss ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Tirzepatide (Zepbound for weight loss; Mounjaro for type 2 diabetes; Eli Lilly) consistently reduced body weight regardless of pretreatment body mass index (BMI) and reduced body weight and waist ...

The Best Weight Loss Supplements for Women This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: The best ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...